Clinical Trial Update: Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial of IBI308 in advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• IBI308 (IBI308)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-01-19